LFVN — LifeVantage Corporation

Summary of LifeVantage Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $48.9 million, down 27.8% year-over-year from $67.8 million in Q2 2025, but up 2.9% sequentially from Q1 2026.
• MINDBODY GLP-1 Sales: Decreased by $16.2 million compared to the prior year, significantly impacting overall revenue.
• LoveBiome Contribution: Generated $4.1 million in revenue following the acquisition.
• Gross Profit Margin: 74%, down from 80.5% in the prior year; adjusted gross profit margin at 78.8% after a $2.4 million inventory reserve.
• GAAP Operating Income: $500,000, down from $3.4 million year-over-year; adjusted operating income at $2.6 million.
• Net Income: GAAP net income of $300,000 ($0.02 per share) compared to $2.6 million ($0.19 per share) in Q2 2025; adjusted net income at $1.9 million ($0.15 per share).
• Adjusted EBITDA: $3.9 million (7.9% of revenue), down from $6.5 million (9.6% of revenue) in the prior year.
• Cash Position: $10.2 million in cash with no debt; $60 million share repurchase program announced.

2. Strategic Updates and Business Highlights

• LoveBiome Integration: Successfully integrated the LoveBiome team, launching two new products—Axila X and Phytopower B—expected to drive engagement and diversify the product portfolio.
• Shopify Partnership: Progressing with a partnership aimed at modernizing e-commerce capabilities, enhancing customer experience, and improving conversion rates.
• Product Development: Continued focus on the HealthyEdge stack and the patent-pending P84 product, which are gaining traction in the gut health market.

3. Forward Guidance and Outlook

• Revenue Guidance for Fiscal 2026: Expected to be between $185 million and $200 million.
• Adjusted EBITDA Guidance: Projected between $15 million and $19 million.
• Adjusted EPS Guidance: Expected to be in the range of $0.60 to $0.80 per diluted share, reflecting current business trends and competitive dynamics.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant drop in revenue primarily due to increased competition in the GLP-1 market, with pharmaceutical alternatives becoming more accessible and affordable.
• Active Accounts: Total active accounts decreased by 25.2%, indicating a decline in customer engagement.
• Inventory Reserve: A conservative inventory reserve was recognized due to overestimation of demand for the MINDBODY product, reflecting a need for better demand forecasting.
• Profitability Pressure: Increased selling, general, and administrative expenses as a percentage of revenue due to lower sales volume and elevated event-related costs.

5. Notable Q&A Insights

• MINDBODY Marketing Strategy: The company is implementing a multi-faceted marketing approach including discounts, events, and customer engagement tools to revitalize sales.
• LoveBiome Financial Impact: Clarified that the $3.7 million cash outlay was the purchase price for LoveBiome, with future earn-out potential based on revenue targets.
• Competitive Positioning: Management remains optimistic about the MINDBODY product's potential due to its natural formulation, despite current competitive pressures.
• Future Revenue Expectations: Anticipated stabilization and potential growth in the second half of the fiscal year, particularly with the integration of LoveBiome products.

This summary encapsulates the key aspects of LifeVantage's Q2 2026 earnings call, highlighting both the challenges faced and the strategic initiatives underway to drive future growth.